Home › Funds › Fidelity › Select Health Care Portfolio
Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007466
Share classes and tickers: FHCLX (C000272243), FHCNX (C000272244), FHCPX (C000272245), FHCQX (C000272241), FHCRX (C000272242), FSPHX (C000020440)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 757 with, 15 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 15 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 93.6% | 719 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 6 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 14 items (1.9% of the 745 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Kenneth A. Clark | Withhold | FOR — 15 of 21 Fidelity funds | Against | Passed (calculated), 96.1% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Mahkam Zanganeh | Withhold | FOR — 15 of 21 Fidelity funds | Against | Passed (calculated), 98.5% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Manmeet S. Soni | Withhold | FOR — 15 of 21 Fidelity funds | Against | Passed (calculated), 98.4% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Robert W. Duggan | Withhold | FOR — 15 of 21 Fidelity funds | Against | Passed (calculated), 98.3% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Yu (Michelle) Xia | Withhold | FOR — 15 of 21 Fidelity funds | Against | Passed (calculated), 98.3% support |
| Summit Therapeutics Inc. | 2026-06-10 | Approval, by a non-binding advisory vote, of the compensation of our named executive officers. | For | AGAINST — 17 of 25 Fidelity funds | For | Passed (calculated), 96.2% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Erik Harris | Withhold | FOR — 12 of 17 Fidelity funds | Against | Passed (calculated), 81.2% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Nerissa Kreher | Withhold | FOR — 12 of 17 Fidelity funds | Against | Passed (calculated), 76.6% support |
| Galecto, Inc. | 2026-02-09 | Approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of the Common Stock from 300,000,000 to 500,000,000. | Against | FOR — 3 of 3 Fidelity funds | Against | — |
| Galecto, Inc. | 2026-02-09 | Approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3, 4 and/or 5. | Against | FOR — 3 of 3 Fidelity funds | Against | — |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith | Withhold | FOR — 14 of 25 Fidelity funds | Against | Passed (calculated), 86.9% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D. | Withhold | FOR — 13 of 25 Fidelity funds | Against | Passed (calculated), 73.0% support |
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Compensation Report of Corporate Officers | For | AGAINST — 7 of 12 Fidelity funds | For | — |
| Sartorius Stedim Biotech SA | 2026-03-24 | Approve Remuneration Policy of CEO | For | AGAINST — 7 of 12 Fidelity funds | For | — |
Download all 14 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 84.7% of this fund’s 772 such votes could be given a sector; the other 118 (15.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 585 | 14 | 2.4% |
| Industrials | 37 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Technology | 15 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 455 | 0 |
| Audit-related | 107 | 0 |
| Say-on-Pay | 88 | 0 |
| Compensation | 47 | 0 |
| Corporate Governance | 44 | 9 |
| Capital Structure | 32 | 0 |
| Extraordinary Transactions | 4 | 0 |
| Other Social Issues | 4 | 3 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $585M | 10 | 2 |
| Danaher Corporation | May 5, 2026 | $435M | 14 | 0 |
| Johnson & Johnson | April 23, 2026 | $385M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $318M | 8 | 1 |
| Moderna, Inc. | May 6, 2026 | $314M | 5 | 0 |
| argenx SE | November 18, 2025 | $266M | 1 | 0 |
| Boston Scientific Corporation | April 30, 2026 | $214M | 17 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $181M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| April 22, 2026 | The Cigna Group | Shareholder Proposal - Shareholder Right to Act by Written Consent Shareholder proposal | Against | For |
These funds reported the same votes as Select Health Care Portfolio in the latest season (or all but a few items), so they share this page:
786 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Select Health Care Portfolio (FHCLX) voted at 100 shareholder meetings of 98 companies, on 786 ballot items in all. Where management made a recommendation, the fund followed it on 98.1% of the items and voted against it 15 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 15 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (93.6% against 94.1%). It voted differently from most Fidelity funds on 14 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.